Oncothyreon Inc (ONTY) 2.96 $ONTY
Oncothyreon Announces Third Quarter 2015 Financial Results Conference Call
GlobeNewswire - Thu Oct 29, 7:00AM CDT
Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, November 5, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its third quarter 2015 financial results and provide a corporate update and review of its pipeline of products in development.
ONTY: 2.96 (-0.02)
Market Has a Mood Swing to the Upside
at The Street - Thu Oct 15, 3:12PM CDT
Gloom is gone as likelihood of Fed rate hike fades.
BLUE: 77.13 (-1.96), NFLX: 108.38 (+3.26), EYES: 5.88 (-0.37), TRVN: 9.62 (-0.27), ESPR: 24.00 (-0.04), FB: 101.97 (-2.91), BEAT: 13.02 (-0.15), WMT: 57.24 (-0.72), ONTY: 2.96 (-0.02)
'Bad News Is Good News' Is Working
at The Street - Thu Oct 15, 12:43PM CDT
Sorry, bears, but downside market momentum hasn't materialized.
BLUE: 77.13 (-1.96), NFLX: 108.38 (+3.26), EYES: 5.88 (-0.37), TRVN: 9.62 (-0.27), ESPR: 24.00 (-0.04), FB: 101.97 (-2.91), BEAT: 13.02 (-0.15), WMT: 57.24 (-0.72), ONTY: 2.96 (-0.02)
Can 'Bad News Is Good' Continue to Work?
at The Street - Thu Oct 15, 9:45AM CDT
The bulls are more worried about catching a lift then they are about being logical.
BLUE: 77.13 (-1.96), NFLX: 108.38 (+3.26), EYES: 5.88 (-0.37), TRVN: 9.62 (-0.27), ESPR: 24.00 (-0.04), FB: 101.97 (-2.91), BEAT: 13.02 (-0.15), WMT: 57.24 (-0.72), ONTY: 2.96 (-0.02)
Flow of Bad News Pours Over Market
at The Street - Wed Oct 14, 3:17PM CDT
Wal-Mart sets the tone, but selling hasn't been bad enough to kill rally.
BLUE: 77.13 (-1.96), AMZN: 625.90 (-0.65), TRVN: 9.62 (-0.27), TSLA: 206.93 (-4.70), FB: 101.97 (-2.91), WMT: 57.24 (-0.72), BAC: 16.78 (-0.31), WFC: 54.14 (-0.95), GNCA: 4.79 (-0.01), BA: 148.07 (+0.89), INTC: 33.86 (-0.17), ONTY: 2.96 (-0.02), ASML: 92.79 (+0.73), NFLX: 108.38 (+3.26), ESPR: 24.00 (-0.04), JPM: 64.25 (-0.96), BEAT: 13.02 (-0.15), GOOGL: 737.39 (-7.46), IWM: 115.34 (-0.53), AAPL: 119.50 (-1.03)
A Market Malaise
at The Street - Wed Oct 14, 12:37PM CDT
But the mood shifts quite fast on upticks.
BLUE: 77.13 (-1.96), TRVN: 9.62 (-0.27), TSLA: 206.93 (-4.70), FB: 101.97 (-2.91), BAC: 16.78 (-0.31), WFC: 54.14 (-0.95), GNCA: 4.79 (-0.01), INTC: 33.86 (-0.17), ONTY: 2.96 (-0.02), ASML: 92.79 (+0.73), NFLX: 108.38 (+3.26), ESPR: 24.00 (-0.04), JPM: 64.25 (-0.96), BEAT: 13.02 (-0.15), GOOGL: 737.39 (-7.46), AAPL: 119.50 (-1.03)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 3.93 (-0.14), BIIB: 290.51 (-3.21), NWBO: 4.88 (+0.01), CVM: 0.53 (-0.01), CLDX: 12.06 (-0.22), MACK: 9.34 (-0.22), INO: 6.33 (-0.13), NLNK: 38.27 (+0.89), JUNO: 51.76 (+0.37), GALE: 1.68 (-0.05), IMMU: 2.99 (+0.08), ADXS: 11.09 (-0.66), ADRO: 27.01 (+0.11), IMGN: 11.70 (+0.16), AMGN: 158.18 (-2.40), SPPI: 5.21 (+0.10), LLY: 81.57 (-0.43), BMY: 65.95 (-1.36), GSK: 43.06 (+0.27), SRNE: 8.64 (-0.26), ONTY: 2.96 (-0.02), IMUC: 0.39 (-0.01), PGNX: 7.34 (-0.12), ARGS: 5.06 (-0.05), GBIM: 2.48 (-0.09), BLCM: 12.51 (-0.50), SGEN: 41.49 (-0.65), KITE: 68.05 (-0.72), MRK: 54.66 (-0.21)
Late Buying Spurs Intraday Bounce
at The Street - Thu Sep 24, 3:17PM CDT
Mood improves, but there are still lots of reasons to worry.
CANF: 3.33 (+0.18), TRVN: 9.62 (-0.27), SPY: 207.93 (-0.90), LBIO: 6.47 (-0.14), CCRN: 13.50 (-0.15), CAT: 72.99 (+1.02), ONTY: 2.96 (-0.02)
Commodities + China + Europe = Bad Mood
at The Street - Thu Sep 24, 11:13AM CDT
The attitude is, 'I just want out and I don't much care about the price it takes.'
CANF: 3.33 (+0.18), TRVN: 9.62 (-0.27), SPY: 207.93 (-0.90), LBIO: 6.47 (-0.14), CCRN: 13.50 (-0.15), CAT: 72.99 (+1.02), ONTY: 2.96 (-0.02)
Commit To Purchase Oncothyreon At $3, Earn 36.5% Annualized Using Options
StockOptionsChannel.com - Tue Sep 22, 10:39AM CDT
Investors eyeing a purchase of Oncothyreon Inc shares, but tentative about paying the going market price of $3.26/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
ONTY: 2.96 (-0.02)
Expert Briefing on Biotechnology Stocks -- Baxalta, Opko Health, Spectrum Pharma, Arrowhead Research, and Oncothyreon
PR Newswire - Tue Sep 22, 7:20AM CDT
Equity Research Institute has initiated coverage on the following equities: Baxalta Inc. (NYSE: BXLT), Opko Health Inc. (NYSE: OPK), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Arrowhead Research Corporation (NASDAQ: ARWR), and Oncothyreon Inc. (NASDAQ: ONTY). Free research report on Baxalta can be accessed at https://www.erionline.net/BXLT.pdf On Monday, September 21, 2015, the NASDAQ Composite ended at 4,828.96, up 0.04%, the Dow Jones Industrial Average advanced 0.77%, to finish the day at 16,510.19, and the S&P 500 closed at 1,966.97, up 0.46%. The gains were broad based as seven out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
ARWR: 5.15 (-0.04), OPK: 9.45 (+0.06), SPPI: 5.21 (+0.10), BXLT: 34.46 (+0.01), ONTY: 2.96 (-0.02)
'Sell the News' Reaction Is Quite Logical
at The Street - Fri Sep 18, 3:08PM CDT
After poor close on Thursday, market trends down all day.
TRVN: 9.62 (-0.27), SPY: 207.93 (-0.90), LBIO: 6.47 (-0.14), ONTY: 2.96 (-0.02), EXEL: 6.02 (+0.14)
Time to Do Some Stock-Picking
at The Street - Fri Sep 18, 10:12AM CDT
But manage trades closely as opportunities develop.
TRVN: 9.62 (-0.27), SPY: 207.93 (-0.90), LBIO: 6.47 (-0.14), ONTY: 2.96 (-0.02), EXEL: 6.02 (+0.14)
4 Stocks Under $10 to Trade for Big Breakouts
at The Street - Thu Sep 17, 1:10PM CDT
These stocks under $10 are within range of triggering breakout trades.
CRMD: 2.54 (-0.16), TLYS: 7.29 (+0.22), TRUE: 6.14 (-0.04), ONTY: 2.96 (-0.02)
Cracks Are Starting to Show in China's Great Wall; 4 Stocks in The Defensive Healthcare Sector Worth a Second Look to Protect Your Portfolio
ACCESSWIRE - Thu Aug 13, 8:49AM CDT
WINDSOR, ON / ACCESSWIRE / August 13, 2015 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and healthcare stocks making news and subsequent market moves, today alerts investors to some alarming news out of China.
IYY: 104.16 (-0.45), IYH: 150.03 (-0.74), ONVO: 3.01 (-0.04), MRK: 54.66 (-0.21), LBIO: 6.47 (-0.14), ONTY: 2.96 (-0.02)
Oncothyreon reports 2Q loss
Automated Insights - Thu Aug 06, 5:57PM CDT
SEATTLE (AP) _ Oncothyreon Inc. (ONTY) on Thursday reported a loss of $10.9 million in its second quarter.
ONTY: 2.96 (-0.02)
Oncothyreon Reports Second Quarter 2015 Financial Results
GlobeNewswire - Thu Aug 06, 3:09PM CDT
Oncothyreon Inc. (NASDAQ:ONTY) today reported financial results for the second quarter ended June 30, 2015.
ONTY: 2.96 (-0.02)
Oncothyreon Announces Second Quarter 2015 Financial Results Conference Call
GlobeNewswire - Thu Jul 30, 7:00AM CDT
Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, August 6, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its second quarter 2015 financial results.
ONTY: 2.96 (-0.02)
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 117.04 (+3.24), ARQL: 2.26 (-0.01), GALE: 1.68 (-0.05), EXEL: 6.02 (+0.14), XLRN: 31.21 (+0.58), INCY: 117.53 (+0.50), IMGN: 11.70 (+0.16), GSK: 43.06 (+0.27), ONTY: 2.96 (-0.02), AZN: 31.89 (-0.35), MRK: 54.66 (-0.21), AVEO: 1.16 (-0.01), PBYI: 82.42 (-4.38), KPTI: 13.35 (+0.11), NVS: 90.43 (-0.53)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 6.41 (-0.22), BLUE: 77.13 (-1.96), AMBA: 49.44 (-0.94), NFLX: 108.38 (+3.26), EYES: 5.88 (-0.37), AMZN: 625.90 (-0.65), ZIOP: 11.39 (-0.53), LNKD: 240.87 (+23.87), FB: 101.97 (-2.91), RCPT: 231.96 (-0.03), LBIO: 6.47 (-0.14), INTC: 33.86 (-0.17), ONTY: 2.96 (-0.02), CELG: 122.71 (-2.22)
Oncothyreon Announces Third Quarter 2015 Financial Results Conference Call
GlobeNewswire - Thu Oct 29, 7:00AM CDT
Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, November 5, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its third quarter 2015 financial results and provide a corporate update and review of its pipeline of products in development.
ONTY: 2.96 (-0.02)
Market Has a Mood Swing to the Upside
at The Street - Thu Oct 15, 3:12PM CDT
Gloom is gone as likelihood of Fed rate hike fades.
BLUE: 77.13 (-1.96), NFLX: 108.38 (+3.26), EYES: 5.88 (-0.37), TRVN: 9.62 (-0.27), ESPR: 24.00 (-0.04), FB: 101.97 (-2.91), BEAT: 13.02 (-0.15), WMT: 57.24 (-0.72), ONTY: 2.96 (-0.02)
'Bad News Is Good News' Is Working
at The Street - Thu Oct 15, 12:43PM CDT
Sorry, bears, but downside market momentum hasn't materialized.
BLUE: 77.13 (-1.96), NFLX: 108.38 (+3.26), EYES: 5.88 (-0.37), TRVN: 9.62 (-0.27), ESPR: 24.00 (-0.04), FB: 101.97 (-2.91), BEAT: 13.02 (-0.15), WMT: 57.24 (-0.72), ONTY: 2.96 (-0.02)
Can 'Bad News Is Good' Continue to Work?
at The Street - Thu Oct 15, 9:45AM CDT
The bulls are more worried about catching a lift then they are about being logical.
BLUE: 77.13 (-1.96), NFLX: 108.38 (+3.26), EYES: 5.88 (-0.37), TRVN: 9.62 (-0.27), ESPR: 24.00 (-0.04), FB: 101.97 (-2.91), BEAT: 13.02 (-0.15), WMT: 57.24 (-0.72), ONTY: 2.96 (-0.02)
Flow of Bad News Pours Over Market
at The Street - Wed Oct 14, 3:17PM CDT
Wal-Mart sets the tone, but selling hasn't been bad enough to kill rally.
BLUE: 77.13 (-1.96), AMZN: 625.90 (-0.65), TRVN: 9.62 (-0.27), TSLA: 206.93 (-4.70), FB: 101.97 (-2.91), WMT: 57.24 (-0.72), BAC: 16.78 (-0.31), WFC: 54.14 (-0.95), GNCA: 4.79 (-0.01), BA: 148.07 (+0.89), INTC: 33.86 (-0.17), ONTY: 2.96 (-0.02), ASML: 92.79 (+0.73), NFLX: 108.38 (+3.26), ESPR: 24.00 (-0.04), JPM: 64.25 (-0.96), BEAT: 13.02 (-0.15), GOOGL: 737.39 (-7.46), IWM: 115.34 (-0.53), AAPL: 119.50 (-1.03)
A Market Malaise
at The Street - Wed Oct 14, 12:37PM CDT
But the mood shifts quite fast on upticks.
BLUE: 77.13 (-1.96), TRVN: 9.62 (-0.27), TSLA: 206.93 (-4.70), FB: 101.97 (-2.91), BAC: 16.78 (-0.31), WFC: 54.14 (-0.95), GNCA: 4.79 (-0.01), INTC: 33.86 (-0.17), ONTY: 2.96 (-0.02), ASML: 92.79 (+0.73), NFLX: 108.38 (+3.26), ESPR: 24.00 (-0.04), JPM: 64.25 (-0.96), BEAT: 13.02 (-0.15), GOOGL: 737.39 (-7.46), AAPL: 119.50 (-1.03)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 3.93 (-0.14), BIIB: 290.51 (-3.21), NWBO: 4.88 (+0.01), CVM: 0.53 (-0.01), CLDX: 12.06 (-0.22), MACK: 9.34 (-0.22), INO: 6.33 (-0.13), NLNK: 38.27 (+0.89), JUNO: 51.76 (+0.37), GALE: 1.68 (-0.05), IMMU: 2.99 (+0.08), ADXS: 11.09 (-0.66), ADRO: 27.01 (+0.11), IMGN: 11.70 (+0.16), AMGN: 158.18 (-2.40), SPPI: 5.21 (+0.10), LLY: 81.57 (-0.43), BMY: 65.95 (-1.36), GSK: 43.06 (+0.27), SRNE: 8.64 (-0.26), ONTY: 2.96 (-0.02), IMUC: 0.39 (-0.01), PGNX: 7.34 (-0.12), ARGS: 5.06 (-0.05), GBIM: 2.48 (-0.09), BLCM: 12.51 (-0.50), SGEN: 41.49 (-0.65), KITE: 68.05 (-0.72), MRK: 54.66 (-0.21)
Late Buying Spurs Intraday Bounce
at The Street - Thu Sep 24, 3:17PM CDT
Mood improves, but there are still lots of reasons to worry.
CANF: 3.33 (+0.18), TRVN: 9.62 (-0.27), SPY: 207.93 (-0.90), LBIO: 6.47 (-0.14), CCRN: 13.50 (-0.15), CAT: 72.99 (+1.02), ONTY: 2.96 (-0.02)
Commodities + China + Europe = Bad Mood
at The Street - Thu Sep 24, 11:13AM CDT
The attitude is, 'I just want out and I don't much care about the price it takes.'
CANF: 3.33 (+0.18), TRVN: 9.62 (-0.27), SPY: 207.93 (-0.90), LBIO: 6.47 (-0.14), CCRN: 13.50 (-0.15), CAT: 72.99 (+1.02), ONTY: 2.96 (-0.02)
Commit To Purchase Oncothyreon At $3, Earn 36.5% Annualized Using Options
StockOptionsChannel.com - Tue Sep 22, 10:39AM CDT
Investors eyeing a purchase of Oncothyreon Inc shares, but tentative about paying the going market price of $3.26/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
ONTY: 2.96 (-0.02)
Expert Briefing on Biotechnology Stocks -- Baxalta, Opko Health, Spectrum Pharma, Arrowhead Research, and Oncothyreon
PR Newswire - Tue Sep 22, 7:20AM CDT
Equity Research Institute has initiated coverage on the following equities: Baxalta Inc. (NYSE: BXLT), Opko Health Inc. (NYSE: OPK), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Arrowhead Research Corporation (NASDAQ: ARWR), and Oncothyreon Inc. (NASDAQ: ONTY). Free research report on Baxalta can be accessed at https://www.erionline.net/BXLT.pdf On Monday, September 21, 2015, the NASDAQ Composite ended at 4,828.96, up 0.04%, the Dow Jones Industrial Average advanced 0.77%, to finish the day at 16,510.19, and the S&P 500 closed at 1,966.97, up 0.46%. The gains were broad based as seven out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
ARWR: 5.15 (-0.04), OPK: 9.45 (+0.06), SPPI: 5.21 (+0.10), BXLT: 34.46 (+0.01), ONTY: 2.96 (-0.02)
'Sell the News' Reaction Is Quite Logical
at The Street - Fri Sep 18, 3:08PM CDT
After poor close on Thursday, market trends down all day.
TRVN: 9.62 (-0.27), SPY: 207.93 (-0.90), LBIO: 6.47 (-0.14), ONTY: 2.96 (-0.02), EXEL: 6.02 (+0.14)
Time to Do Some Stock-Picking
at The Street - Fri Sep 18, 10:12AM CDT
But manage trades closely as opportunities develop.
TRVN: 9.62 (-0.27), SPY: 207.93 (-0.90), LBIO: 6.47 (-0.14), ONTY: 2.96 (-0.02), EXEL: 6.02 (+0.14)
4 Stocks Under $10 to Trade for Big Breakouts
at The Street - Thu Sep 17, 1:10PM CDT
These stocks under $10 are within range of triggering breakout trades.
CRMD: 2.54 (-0.16), TLYS: 7.29 (+0.22), TRUE: 6.14 (-0.04), ONTY: 2.96 (-0.02)
Cracks Are Starting to Show in China's Great Wall; 4 Stocks in The Defensive Healthcare Sector Worth a Second Look to Protect Your Portfolio
ACCESSWIRE - Thu Aug 13, 8:49AM CDT
WINDSOR, ON / ACCESSWIRE / August 13, 2015 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and healthcare stocks making news and subsequent market moves, today alerts investors to some alarming news out of China. IYY: 104.16 (-0.45), IYH: 150.03 (-0.74), ONVO: 3.01 (-0.04), MRK: 54.66 (-0.21), LBIO: 6.47 (-0.14), ONTY: 2.96 (-0.02)
Oncothyreon reports 2Q loss
Automated Insights - Thu Aug 06, 5:57PM CDT
SEATTLE (AP) _ Oncothyreon Inc. (ONTY) on Thursday reported a loss of $10.9 million in its second quarter.
ONTY: 2.96 (-0.02)
Oncothyreon Reports Second Quarter 2015 Financial Results
GlobeNewswire - Thu Aug 06, 3:09PM CDT
Oncothyreon Inc. (NASDAQ:ONTY) today reported financial results for the second quarter ended June 30, 2015.
ONTY: 2.96 (-0.02)
Oncothyreon Announces Second Quarter 2015 Financial Results Conference Call
GlobeNewswire - Thu Jul 30, 7:00AM CDT
Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, August 6, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its second quarter 2015 financial results.
ONTY: 2.96 (-0.02)
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 117.04 (+3.24), ARQL: 2.26 (-0.01), GALE: 1.68 (-0.05), EXEL: 6.02 (+0.14), XLRN: 31.21 (+0.58), INCY: 117.53 (+0.50), IMGN: 11.70 (+0.16), GSK: 43.06 (+0.27), ONTY: 2.96 (-0.02), AZN: 31.89 (-0.35), MRK: 54.66 (-0.21), AVEO: 1.16 (-0.01), PBYI: 82.42 (-4.38), KPTI: 13.35 (+0.11), NVS: 90.43 (-0.53)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 6.41 (-0.22), BLUE: 77.13 (-1.96), AMBA: 49.44 (-0.94), NFLX: 108.38 (+3.26), EYES: 5.88 (-0.37), AMZN: 625.90 (-0.65), ZIOP: 11.39 (-0.53), LNKD: 240.87 (+23.87), FB: 101.97 (-2.91), RCPT: 231.96 (-0.03), LBIO: 6.47 (-0.14), INTC: 33.86 (-0.17), ONTY: 2.96 (-0.02), CELG: 122.71 (-2.22)
